2023’s Unpartnered Assets – Where Are They Now?

Last year, In Vivo spotlighted some of biopharma’s most highly valued yet unpartnered assets. Now it’s time to see if deals have been struck and review how NPVs have changed.

Business concept illustration of a businessman being guided by a hand holding a flashlight uncovering arrow sign.
• Source: Shutterstock

For inclusion in 2023’s list, an asset had to be wholly owned, outside of clinical trial collaborations or small, regional tie-ups, and its developer unlikely to want to launch alone. The table was based on the net present value of the assets, as computed by Evaluate. In Vivo spotlighted 10 assets that could draw attention from dealmakers.

Reviewing the 2023 table, three assets have lost value, according to NPV analysis from Evaluate. These are: Ventyx Biosciences, Inc.’s VTX958, uniQure N.V.’s AMT-130 and ALX Oncology, Inc.’s evorpacept. Of these drugs, VTX958 has been the biggest casualty; Ventyx has suspended development in all indications.

More from Deal-Making

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Deals Shaping The Industry, May 2025

 
• By 

An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By 

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

Deals In Depth: April 2025

 
• By 

Four $1bn+ alliances were penned in April, and one exceeded $2bn.

More from In Vivo

EU Medtech Outlook: The View From MedTech Europe Experts

 
• By 

MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.

‘Confident In Lorundrostat’s Promise’: Mineralys CEO Talks Trials And Next Steps

 

In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.

BioBytes: Qubit Pharmaceuticals Unveils Quantum AI Model For Drug Discovery

 
• By 

Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.